Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1014802 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | OTHER | - |
| Cohort 4 | OTHER | - |
| Cohort 3 | OTHER | - |
| Cohort 2 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Tablets to match GSK1014802 |
| GSK1014802 | DRUG | Sodium channel blocker |
Inclusion Criteria: * Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. * Male or female (of non-child bearing potential) subjects aged between 18 and 55 years. * A female su...
GSK1014802 is an investigational small molecule being developed by Biogen Inc. for bipolar depression. It has completed a Phase 1 clinical trial evaluating its safety, tolerability, and pharmacokinetics in repeat doses. The drug is in early clinical development and is not approved for any indication.
GSK1014802 is being studied for the treatment of bipolar depression, a condition associated with bipolar disorder. Its development is focused on psychiatric indications. The compound remains investigational and has not been approved for clinical use in bipolar depression or any other condition.
Biogen Inc. (ticker: BIIB) is developing GSK1014802. The company is the sponsor behind the clinical program evaluating the compound in bipolar depression. Biogen is a biotechnology company focused on neurological and psychiatric disorders.
GSK1014802 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not received regulatory approval for bipolar depression or any other indication.
GSK1014802 has been evaluated in one completed Phase 1 trial, NCT00908154, titled "Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802." The randomized, double-blind, controlled study enrolled 51 healthy volunteers in the United Kingdom. No active trials are currently listed for this compound.
Yes, GSK1014802 is a small molecule therapeutic. It is being developed as an orally available compound for psychiatric indications, specifically bipolar depression. Small molecule drugs are typically chemically synthesized and can often be administered orally, distinguishing them from biologic therapies.